JP2008520708A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520708A5 JP2008520708A5 JP2007543289A JP2007543289A JP2008520708A5 JP 2008520708 A5 JP2008520708 A5 JP 2008520708A5 JP 2007543289 A JP2007543289 A JP 2007543289A JP 2007543289 A JP2007543289 A JP 2007543289A JP 2008520708 A5 JP2008520708 A5 JP 2008520708A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- lack
- effective amount
- pharmaceutical composition
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 201000006409 renal osteodystrophy Diseases 0.000 claims 3
- 210000002374 sebum Anatomy 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 230000037067 skin hydration Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010050637 Skin tightness Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000036944 Skin dystrophies Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- -1 t-butyldimethylsilyl groups Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62995404P | 2004-11-22 | 2004-11-22 | |
| PCT/US2005/041886 WO2006057913A2 (en) | 2004-11-22 | 2005-11-18 | 2-METHYLENE-19-NOR-(20R)-1-α-HYDROXY-BISHOMOPREGNACALCIFEROL |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008520708A JP2008520708A (ja) | 2008-06-19 |
| JP2008520708A5 true JP2008520708A5 (enExample) | 2009-01-15 |
Family
ID=36498435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543289A Ceased JP2008520708A (ja) | 2004-11-22 | 2005-11-18 | ２−メチレン−１９−ノル−（２０Ｒ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロール |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8222235B2 (enExample) |
| EP (1) | EP1831161B1 (enExample) |
| JP (1) | JP2008520708A (enExample) |
| AU (1) | AU2005309818A1 (enExample) |
| CA (1) | CA2588038A1 (enExample) |
| MX (1) | MX2007006090A (enExample) |
| NZ (1) | NZ555562A (enExample) |
| WO (1) | WO2006057913A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
| AU2005309820B2 (en) * | 2004-11-22 | 2011-06-23 | Wisconsin Alumni Research Foundation | 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol |
| US8222235B2 (en) | 2004-11-22 | 2012-07-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol |
| WO2007117563A2 (en) | 2006-04-05 | 2007-10-18 | Wisconsin Alumni Research Foundation | 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and use thereof |
| US20090281340A1 (en) * | 2006-04-05 | 2009-11-12 | Deluca Hector F | 1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof |
| WO2009086440A1 (en) * | 2007-12-28 | 2009-07-09 | Wisconsin Alumni Research Foundation | 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs |
| CA2710954C (en) * | 2007-12-28 | 2015-07-21 | Wisconsin Alumni Research Foundation | (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs |
| CA2715811A1 (en) | 2008-03-06 | 2009-09-11 | Wisconsin Alumni Research Foundation | Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound |
| US20130178449A1 (en) * | 2011-07-18 | 2013-07-11 | Wisconsin Alumni Research Foundation | 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| CA2062520C (en) | 1991-03-11 | 1998-08-11 | Hector F. Deluca | Synthesis of 1-alpha-hydroxy-secosterol compounds |
| US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| JPH05238937A (ja) | 1992-03-09 | 1993-09-17 | Wisconsin Alumni Res Found | 細胞分化誘発薬剤 |
| US5843028A (en) * | 1992-05-11 | 1998-12-01 | Medical Innovations Corporation | Multi-lumen endoscopic catheter |
| JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物 |
| US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
| US5891865A (en) * | 1996-10-04 | 1999-04-06 | Wisconsin Alumni Research Foundation | Treatment of arthritic disease induced by infectious agents |
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US5936105A (en) * | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
| AU7544501A (en) | 2000-09-08 | 2002-03-22 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US6835723B2 (en) * | 2001-12-13 | 2004-12-28 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form |
| WO2003051828A2 (en) | 2001-12-13 | 2003-06-26 | Wisconsin Alumni Research Foundation | (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| ATE346839T1 (de) * | 2002-03-29 | 2006-12-15 | Wisconsin Alumni Res Found | Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol |
| WO2005051323A2 (en) | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| AU2005309804B9 (en) * | 2004-11-22 | 2011-12-08 | Wisconsin Alumni Research Foundation | 2alpha-methyl-19-nor-(20S)-1alpha-hydroxy-bishomopregnacalciferol and its uses |
| AU2005309820B2 (en) * | 2004-11-22 | 2011-06-23 | Wisconsin Alumni Research Foundation | 2-methylene-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol |
| EP1828115A4 (en) * | 2004-11-22 | 2010-05-05 | Wisconsin Alumni Res Found | 2-METHYLENE-19-NOR (20S) -1ALPHA-HYDROXYTRISHOMOPREGNACALCIFEROL |
| US8222235B2 (en) | 2004-11-22 | 2012-07-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol |
| EP2237837B1 (en) * | 2007-12-28 | 2012-08-22 | Wisconsin Alumni Research Foundation | (20r)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs |
| CA2710954C (en) * | 2007-12-28 | 2015-07-21 | Wisconsin Alumni Research Foundation | (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs |
-
2005
- 2005-11-18 US US11/282,972 patent/US8222235B2/en not_active Expired - Fee Related
- 2005-11-18 WO PCT/US2005/041886 patent/WO2006057913A2/en not_active Ceased
- 2005-11-18 EP EP05848203.5A patent/EP1831161B1/en not_active Expired - Lifetime
- 2005-11-18 MX MX2007006090A patent/MX2007006090A/es active IP Right Grant
- 2005-11-18 NZ NZ555562A patent/NZ555562A/en not_active IP Right Cessation
- 2005-11-18 JP JP2007543289A patent/JP2008520708A/ja not_active Ceased
- 2005-11-18 AU AU2005309818A patent/AU2005309818A1/en not_active Abandoned
- 2005-11-18 CA CA002588038A patent/CA2588038A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505739A5 (enExample) | ||
| JP2009532458A5 (enExample) | ||
| JP2008520689A5 (enExample) | ||
| JP2005529878A5 (enExample) | ||
| JP2008520709A5 (enExample) | ||
| JP2008520703A5 (enExample) | ||
| JP2008530110A5 (enExample) | ||
| JP2008520708A5 (enExample) | ||
| JP2009536191A5 (enExample) | ||
| US20160367707A1 (en) | Halogenated compounds for cancer imaging and treatment and methods for their use | |
| JP2010540555A5 (enExample) | ||
| CN109843338B (zh) | 含有psma抑制剂的18f标记的三唑 | |
| JP2010504995A5 (enExample) | ||
| JP2008520705A5 (enExample) | ||
| JP2008520691A5 (enExample) | ||
| JP2008530109A5 (enExample) | ||
| CA2597624A1 (en) | 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2 | |
| JP2013522369A5 (enExample) | ||
| JP2011527695A5 (enExample) | ||
| JP2011527699A5 (enExample) | ||
| JP2008520710A5 (enExample) | ||
| CA2588415A1 (en) | 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses | |
| JP2009533483A5 (enExample) | ||
| JP2010504994A5 (enExample) | ||
| CA2531505A1 (en) | (20s)-1.alpha.-hydroxy-2-methylene-19-nor-vitamin d3 and its uses |